Nationwide, there is a significant shortage of pediatric endocrinologists, particularly true at academic institutions. The primary goal for this competing renewal T32 proposal is to facilitate the training of highly skilled academic pediatric endocrinologists by providing concentrated research training in either basic or patient-oriented science during fellowship. Our secondary objective is to provide an environment that will facilitate the successful advancement of women into academic careers. Fellows selected for this training program must demonstrate a strong interest in a future academic career. They will be asked to propose research plans that will allow their progression into the ranks of academic pediatric faculties. Fellows will be matched with mentors that can support their goals for research training and provide guidance for advancement to the next phase of their academic careers. Faculty mentors will be selected for their ability to facilitate this transition and to impart a culture of responsible, rigorous, and robust science as is the tradition of the Pediatric Department at University of Minnesota. Trainees choose between a basic science or a clinical science research tack. Trainees on the clinical research track will obtain a formal Master's Degree in Clinical Research. Since this program began in 2002, it has recruited 6 women (1 per year). Four have completed the program, two of whom are tenure-track academic faculty (one with a Children's Miracle Network grant and the other with a K12). The two fellows still in training are highly likely to enter academic medicine. The historic strengths of this institution and its programs afford trainees an exceptionally diverse and high quality educational experience.
Given the current epidemic of pediatric diabetes and obesity and the profound impact these diseases are likely to have on future adult health, there is an urgent public health need for physician scientists trained to be able to tackle critical endocrine problems through innovative scientific discovery and its translation into clinical practice.
|Forlenza, G P; Nathan, B M; Moran, A M et al. (2016) Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation. Am J Transplant 16:527-34|
|Halvorsen, Tanya; Moran, Antoinette; Jacobs Jr, David R et al. (2015) Relation of Cardiometabolic Risk Factors between Parents and Children. J Pediatr 167:1049-56.e2|
|Forlenza, Gregory P; Calhoun, Amy; Beckman, Kenneth B et al. (2015) Next generation sequencing in endocrine practice. Mol Genet Metab 115:61-71|
|Forlenza, Gregory P; Polgreen, Lynda E; Miller, Bradley S et al. (2014) Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation. Pediatr Blood Cancer 61:1142-3|
|Forlenza, Gregory P; Chinnakotla, Srinath; Schwarzenberg, Sarah J et al. (2014) Near-euglycemia can be achieved safely in pediatric total pancreatectomy islet autotransplant recipients using an adapted intravenous insulin infusion protocol. Diabetes Technol Ther 16:706-13|
|Sunni, Muna; Bellin, Melena D; Moran, Antoinette (2013) Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes 14:295-8|
|Ode, Katie Larson; Gray, Heather L; Ramel, Sara E et al. (2012) Decelerated early growth in infants of overweight and obese mothers. J Pediatr 161:1028-34|
|Frohnert, Brigitte I; Ode, Katie Larson; Moran, Antoinette et al. (2010) Impaired fasting glucose in cystic fibrosis. Diabetes Care 33:2660-4|
|Ode, Katie Larson; Frohnert, Brigitte; Laguna, Theresa et al. (2010) Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 11:487-92|
|Polgreen, L E; Plog, M; Schwender, J D et al. (2009) Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 44:279-85|
Showing the most recent 10 out of 12 publications